Decoding Ozempic’s Efficacy: What Percentage of People Doe

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists work effectively for approximately 60-75% of patients who use them for weight management, according to clinical trial data. However, the remaining 25-40% may experience minimal response, highlighting the importance of understanding individual variation in treatment outcomes.

Response to GLP-1 therapy depends on multiple factors beyond the medication itself: metabolic health, insulin sensitivity, genetic predispositions, and baseline body composition all play roles. PlexusDx emphasizes precision wellness by helping patients understand their individual context before and during treatment.

Clinical Response Rates and What They Really Mean

Clinical trials define GLP-1 success as achieving at least 5% body weight reduction over 68 weeks. Real-world data suggests 60-75% of patients meet this threshold, while some achieve 10-15% reductions. Individual variation is substantial and influenced by adherence, dosing, lifestyle, and metabolic factors.

Response rates vary by trial population, baseline weight, comorbidities, and medication formulation. Studies on semaglutide show higher efficacy in insulin-resistant populations compared to insulin-sensitive patients, suggesting metabolic phenotype influences outcomes significantly.

Biomarkers and Genetic Factors That May Predict Response

Research increasingly suggests that baseline insulin resistance, HbA1c levels, and inflammatory markers correlate with GLP-1 response. Patients with higher insulin resistance often see more pronounced appetite suppression and weight loss effects. Additionally, genetic variations in GLP-1 receptor, GIPR, and metabolic genes may influence individual treatment outcomes.

The Precision Peptide Genetic Test evaluates key variants in peptide pathways including GLP1R rs6923761 and GIPR rs1800437. These predispositions may help provide context for how your metabolism responds to GLP-1 therapy and should be interpreted with a qualified healthcare provider.

Factor	Potential Influence on Response
Baseline Insulin Resistance	Higher resistance often correlates with stronger appetite suppression and weight loss
GLP1R Gene Variant (rs6923761)	Genetic predisposition may influence receptor sensitivity and medication response
GIPR Gene Variant (rs1800437)	Co-agonism effects vary; predisposition may affect glucose and hunger signaling
FTO Gene Variant (rs9939609)	Predisposition relates to baseline appetite regulation and weight loss potential
Baseline HbA1c Level	Higher levels suggest greater metabolic dysregulation; may predict stronger GLP-1 response

Non-Responders: Why Some Patients Don't See Expected Results

Approximately 25-40% of patients experience minimal weight loss or appetite suppression on GLP-1 therapy. Contributing factors include inadequate dosing, poor adherence, rapid GI tolerance, genetic factors reducing receptor sensitivity, or underlying metabolic conditions limiting response.

Secondary causes of non-response include severe insulin resistance managed by other medications, certain medications that oppose GLP-1 effects, and conditions affecting GI motility. A provider should evaluate these factors before concluding a GLP-1 is ineffective for an individual.

Safety, Provider Evaluation, and Who Should Start GLP-1 Therapy

GLP-1 receptor agonists require careful screening for contraindications including personal or family history of medullary thyroid cancer, MEN2 syndrome, severe gastroparesis, or acute pancreatitis. Baseline kidney function, blood pressure, and hydration status should be assessed before initiation.

A qualified healthcare provider should evaluate your medical history, current medications, weight loss goals, and metabolic health before recommending GLP-1 therapy. Genetic insights and biomarker testing can support a more informed conversation with your provider about whether this treatment aligns with your individual health profile.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for how your individual peptide pathways—including GLP-1 and GIPR signaling—function at baseline. Key variants like GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609 reveal predispositions in appetite regulation and metabolic response. These insights should be interpreted with a qualified healthcare provider as part of a broader clinical evaluation.

Genetic predisposition is not deterministic; it reveals how your metabolism may be wired toward certain responses. The Precision Peptide Genetic Test reveals predispositions in peptide pathways relevant to GLP-1 therapy, but does not predict exact medication response or guarantee outcomes. Biomarkers like insulin resistance, HbA1c, and inflammatory markers provide additional context.

Understanding your genetic predispositions and baseline biomarkers can support a more informed conversation with your provider about GLP-1 candidacy, medication selection, dosing strategy, and realistic outcome expectations. PlexusDx provides access to compounded GLP-1 options from licensed 503A pharmacies—ranging from microdose protocols at $129/month to full-strength formulations—allowing providers to tailor treatment to individual response patterns.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What percentage of people actually see weight loss results from GLP-1 medications?

Approximately 60-75% of patients achieve at least 5% body weight reduction on GLP-1 therapy. Individual outcomes vary based on baseline metabolism, adherence, dosing, and genetic factors. A provider can help determine realistic expectations for your specific situation.

Why do some people not respond to GLP-1 medications?

Non-response may result from inadequate dosing, poor adherence, genetic factors affecting receptor sensitivity, underlying metabolic conditions, or drug interactions. Baseline insulin resistance and metabolic phenotype significantly influence response patterns in clinical populations.

How can I know if GLP-1 therapy will work for me before starting?

A provider should assess your baseline insulin resistance, HbA1c, kidney function, and medical history. PlexusDx's Precision Peptide Genetic Test ($99 add-on or $298 standalone) reveals predispositions in peptide pathways, which may help support a more informed provider conversation about candidacy and expectations.

Are there safety concerns I should discuss with my provider before starting GLP-1?

Yes. Contraindications include personal/family history of medullary thyroid cancer, MEN2 syndrome, severe gastroparesis, and acute pancreatitis. Your provider should also evaluate kidney function, blood pressure, and current medications to ensure GLP-1 is appropriate for you.

Can genetic testing predict how well GLP-1 will work for me?

Genetic predispositions in peptide pathways reveal potential wiring for appetite regulation and metabolic response, but do not predict exact medication response. The Precision Peptide Genetic Test identifies variants like GLP1R rs6923761 and GIPR rs1800437 to support informed provider conversations, not guarantee outcomes.

Decoding Ozempic’s Efficacy: What Percentage of People Does Ozempic Work For?